11AI | pdb_000011ai

Cryo-EM structure of a bovine CLC-K S68N/R355K chloride channel with inhibitor M-BIM1

  • Classification: TRANSPORT PROTEIN
  • Organism(s): Bos taurus
  • Expression System: Homo sapiens
  • Mutation(s): Yes 

  • Deposited: 2026-02-13 Released: 2026-09-09 
  • Deposition Author(s): Chien, C.-T., Chiu, W., Maduke, M.
  • Funding Organization(s): National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease (NIH/NIDDK), National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 11AI

This is version 1.1 of the entry. See complete history

Literature

Mechanism of gating and isoform-specific inhibition in renal CLC chloride channels.

Chien, C.T.Sobecks-Doherty, B.L.Powers, A.S.Das, A.Kreiter, J.Barry, C.N.Chen, M.Hinman, A.Petrakian, C.F.Williams, B.Wood, C.A.P.Xu, M.Dror, R.O.Chiu, W.Maduke, M.

(2026) Proc Natl Acad Sci U S A 123: e2605886123-e2605886123

  • DOI: https://doi.org/10.1073/pnas.2605886123
  • Primary Citation Related Structures: 
    11AH, 11AI, 11AK, 11AM, 11EU, 11EV

  • PubMed Abstract: 

    Hyponatremia is a prevalent disorder marked by excess water retention and substantial morbidity, motivating interest in the chloride channel CLC-Ka as a therapeutic target. Selectively inhibiting CLC-Ka without affecting the closely related CLC-Kb is essential for preventing serious side effects. However, developing isoform-selective inhibitors has been challenging because most small molecules do not distinguish between CLC-Ka and CLC-Kb, and the basis for selectivity in the few known exceptions remains unclear. The small molecule BIM1 preferentially inhibits CLC-Ka over CLC-Kb, providing an opportunity to dissect isoform-specific pharmacology. To investigate this mechanism, we determined cryo-EM structures of BIM1 and BIM15, a related nonselective analog, bound to a CLC-K variant engineered to match the human CLC-Ka binding pocket. Structural and computational analyses reveal that inhibition and isoform selectivity are anchored by interactions with a conserved lysine, with surrounding binding-site residues subtly tuning the local electrostatic environment to promote or disfavor these contacts. These analyses further identify a dynamic extracellular loop that intermittently occludes the shared pathway accessing the inhibitor-binding site and pore. Bound BIM15 engages this gating loop more extensively than BIM1, suggesting that differential loop engagement contributes to inhibitor selectivity, a prediction validated by mutagenesis. Because loop dynamics block the pore, we examined the structural impact of Ca 2+ , which favors opening, and found the gating loop ordered and withdrawn from the pathway. Together, these findings define how binding-site microenvironments and gating-loop dynamics shape isoform-specific inhibition and pore access in CLC-K channels.


  • Organizational Affiliation
    • Department of Bioengineering, Stanford University, Stanford, CA 94305.

Macromolecule Content 

  • Total Structure Weight: 147.87 kDa 
  • Atom Count: 9,354 
  • Modeled Residue Count: 1,208 
  • Deposited Residue Count: 1,342 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Chloride voltage-gated channel Ka
A, B
671Bos taurusMutation(s): 3 
Gene Names: CLCNKA
UniProt
Find proteins for E1B792 (Bos taurus)
Explore E1B792 
Go to UniProtKB:  E1B792
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupE1B792
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 2.80 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
MODEL REFINEMENTPHENIX1.21.1_5286
RECONSTRUCTIONcryoSPARC

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease (NIH/NIDDK)United StatesR01DK128881
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesR01GM150905

Revision History  (Full details and data files)

  • Version 1.0: 2026-09-09
    Type: Initial release
  • Version 1.1: 2026-09-16
    Changes: Data collection, Database references